Our aim is to uncover the mechanisms underlying cognitive and social alterations relevant to psychiatric and neurodevelopmental disorders with the final goal of developing biologically-based and personalized therapeutic strategies. We employ cross-disciplinary approaches including detailed in vivo studies in genetically modified mice strictly combined with clinical investigations.
Untitled ST - Generic Content Grid
Overreaching Research Goals
Overreaching Research Goals
- To implement more efficient and biologically-supported personalized medicine for cognitive and social alterations relevant to psychiatric and neurodevelopmental disorders.
- To develop a bidirectional mouse-human approach to accelerate the development of precision medicine strategies, with a deeper understanding of the biological mechanisms involved.
- To investigate genetics, circuits, and cell-type specific mechanisms underlying higher-order cognitive and social processes.
- To understand the brain-immune system interplay in modulating cognitive and social functions, their developmental trajectories, and the impact of early treatments.
- February 2020-February 2023: Principal Investigator. Fondazione Telethon – project GGP19103, title: “Improving developmental trajectories in 22q11.2 deletion syndrome by oxytocin: focus on anti-inflammatory effects”.
- September 2019-September 2022: Co-PI, work package leader. AIFA (Agenzia Italiana del Farmaco). Title: “Cannabidiol as an add-on treatment to substance abuse in juvenile patients with psychosis: a double-blind randomized placebo-controlled study (CAT-PSY)”.
- November 2018-November 2021: Principal Investigator. Ricerca Finalizzata Giovani Ricercatori 2016 - Ministero Salute – project GR-2016-02362413, title: “Dysbindin-antipsychotics psychophamarcogenetics: a mouse-human translational study towards personalized healthcare in bipolar disorders”.
- September 2018-September 2020: Supervisor and hosting lab. Marie Sklodowska-Curie individual Fellowships European to Celine Devroye. SOCIALBRAINCIRCUITS.
- July 2018- August 2020: Principal Investigator. Boehringer Ingelheim Pharma. Title: “Role of the frontocortical-parvalbumin system in higher-order cognitive functions and in the onset of cognitive deficits induced by schizophrenia-relevant mutations”.
- October 2018: Principal Investigator. The MINDDS Action of the European COST Association (eCOST). Training school/hands-on workshop in “Convergence Neuroscience: bridging the gap between human patients and animal models of neurodevelopmental disorders”.
- March 2016- December 2018: Principal Investigator. Compagnia di San Paolo grant n. 2015-0321. Title: “Utilizzo di variazioni genetiche in dysbindin-1 (dtnbp1) per lo sviluppo di trattamenti più efficaci e personalizzati per la schizofrenia”.
- September 2015-March 2018: Principal Investigator. Brain & Behavior Research Foundation, 2015 NARSAD Independent Investigator grant n. 23234; Title: “Use of genetic-driven dysbindin-1 (DTNBP1) variations for more effective and personalized treatments in First Episode of Psychosis”.
- January 2013-January 2017: Principal Investigator. Roche Postdoc Fellowship Program; title: “D2L/S-dysbindin genetic interaction: towards early detection and personalized interventions for cognitive deficits and schizophrenia”.
More grants have been won by our PI, before the official line kick off
- January 2014-December 2015: in charge of a work package. 2013 NARSAD Young Investigator grant. Title: “Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11 microdeletion syndrome genetically at high risk for psychosis: A randomised, double blind, placebo-controlled treatment trial”.
- January 2013-May 2016: Principal Investigator. Ricerca Finalizzata Giovani Ricercatori 2010 - Ministero Salute – project GR-2010-2315883, title: “Schizophrenia pathogenetic mechanisms associated to dysbindin dysfunctions in fly and mouse models”.
- September 2010-September 2014: Principal Investigator. Marie Curie FP7-Reintegration-Grants Call identifier: FP7-PEOPLE-2010-RG Grant N° 268247 – "SCHIZOGENES".
- August 2008-August 2010: Principal Investigator. NIMH Julius Axelrod Memorial Fellowship Training Award. Behavioral characterization of genetically modified mice for schizophrenia-associated susceptibility genes.
- Alessandro Gozzi: structural and functional MRI in mouse models
- Ferruccio Pisanello: optogenetics and fiberphotometry probes for in vivo manipulations
- Laura Cancedda: electrophysiology and neurodevelopmental disorders
- Paolo Decuzzi: new drug delivery systems targeting the brain
- Pier Paolo Pompa: colorimetric kit for genetic tests in humans
- Roberto Marotta: electron microscopy analyses
- Stefano Gustincich: SINEUPs for the OXTergic system and for the 22q11.2DS
- Vittorio Murino & Diego Sona: software development and pattern analyses of complex behaviors
- Stefano Vicari (Bambino Gesu’ Hospital): clinical data and samples
- Gianfranco Spalletta (Santa Lucia Hospital): human MRI, clinical data and samples
- Paolo Brambilla (Policlinico Milano): human MRI, clinical data and samples
- Andrea de Bartolomeis, Felice Iasevoli (Policlinico Napoli): clinical data and samples
- Maria Nobile (IRCCS Medea): clinical data and samples
- Stephan Eliez (Switzerland): human MRI, clinical data and samples
- Cyndi Weickert (Australia): post mortem human brains
- Daniel Weinberger (USA): post mortem human brains and human genetic data
- Oliver Howes (UK): human PET, clinical data
- Ofer Yizhar (Israel): optogenetics
- Cecilia Flores (Canada): dopamine neurodevelopment
- Giovanni Marsicano (France): cannabinoid system
- Valery Grinevich (Germany): oxytocin system
- Davide Ragozzino (Roma): microglia
- Bice Chini (Milano): oxytocin system
- Fabio Fumagalli (Milano): cellular mechanisms
- Kuan Wang (USA): genetically modified mouse models
- Amanda Law (USA): genetically modified mouse models
- Angelo Contarino (France): CRF system
- Giorgio Carmignoto (Padova): astrocytes
- Roberto Arban, Moritz von Heimendahl (Germany): attentional set shifting task
- Filippo Drago, Gian Marco Leggio, Gabriella Trigilio (Catania): genetically modified mouse models
- Sara De Martin (Padova): immune system
- Mary De Luca (Cagliari): dopamine microdialysis